Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.

de Mesquita YLL, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao EMH, Carvalho PEP, da Silva CHA, Cardoso R, Moura FA, Rafalskiy VV

International journal of obesity (2005)17 Jul 2023Cited by 40 (Europe PMC)

PMID37460681DOI10.1038/s41366-023-01337-xPepBankPUB-37460681

Publisher page PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanSystematic reviewEfficacy outcome
In adults in randomized trials, tirzepatide 5 mg lowered body weight more than placebo (mean difference -7.7 kg).
In plain wordsIn adults in trials, tirzepatide 5 mg led to more weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody weight mean difference versus placebo, 5 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Measurements
Mean difference in body weight
−7.7 kg
tirzepatide 5 mg vs placebo
Source sentences
Summary
Pooled analysis showed that tirzepatide 5 mg, 10 mg, and 15 mg were more effective than placebo, with MD in body weight of -7.7 kg (95% CI -11.0, -4.4; p < 0.001), -11.6 kg (95% CI -18.8, -4.3; p = 0.002), and -11.8 kg (95% CI -17.4, -6.2; p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068101
02HumanSystematic reviewEfficacy outcome
In adults in randomized trials, tirzepatide 10 mg lowered body weight more than placebo (mean difference -11.6 kg).
In plain wordsIn adults in trials, tirzepatide 10 mg led to more weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody weight mean difference versus placebo, 10 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Measurements
Mean difference in body weight
−11.6 kg
tirzepatide 10 mg vs placebo
Source sentences
Summary
Pooled analysis showed that tirzepatide 5 mg, 10 mg, and 15 mg were more effective than placebo, with MD in body weight of -7.7 kg (95% CI -11.0, -4.4; p < 0.001), -11.6 kg (95% CI -18.8, -4.3; p = 0.002), and -11.8 kg (95% CI -17.4, -6.2; p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068102
03HumanSystematic reviewEfficacy outcome
In adults in randomized trials, tirzepatide 15 mg lowered body weight more than placebo (mean difference -11.8 kg).
In plain wordsIn adults in trials, tirzepatide 15 mg led to more weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody weight mean difference versus placebo, 15 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Mean difference in body weight
−11.8 kg
tirzepatide 15 mg vs placebo
Source sentences
Summary
Pooled analysis showed that tirzepatide 5 mg, 10 mg, and 15 mg were more effective than placebo, with MD in body weight of -7.7 kg (95% CI -11.0, -4.4; p < 0.001), -11.6 kg (95% CI -18.8, -4.3; p = 0.002), and -11.8 kg (95% CI -17.4, -6.2; p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068103
04HumanSystematic reviewEfficacy outcome
In adults in randomized trials, tirzepatide 5 mg lowered percent body weight more than placebo (mean difference -8.1%).
In plain wordsIn adults in trials, tirzepatide 5 mg led to a larger percent weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreasePercent weight change versus placebo, 5 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Measurements
Mean difference in percent weight change
−8.1%
tirzepatide 5 mg vs placebo
Source sentences
Summary
MD in percent change in weight of -8.1% (95% CI -11.0, -5.2; p < 0.001), -11.9% (95% CI -18.1, -5.6; p < 0.001), and -12.4% (95% CI -17.2, -7.5; p < 0.001), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Pooled analysis showed that tirzepatide 5 mg, 10 mg, and 15 mg were more effective than placebo
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068104
05HumanSystematic reviewEfficacy outcome
In adults in randomized trials, tirzepatide 10 mg lowered percent body weight more than placebo (mean difference -11.9%).
In plain wordsIn adults in trials, tirzepatide 10 mg led to a larger percent weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreasePercent weight change versus placebo, 10 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Measurements
Mean difference in percent weight change
−11.9%
tirzepatide 10 mg vs placebo
Source sentences
Summary
MD in percent change in weight of -8.1% (95% CI -11.0, -5.2; p < 0.001), -11.9% (95% CI -18.1, -5.6; p < 0.001), and -12.4% (95% CI -17.2, -7.5; p < 0.001), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Pooled analysis showed that tirzepatide 5 mg, 10 mg, and 15 mg were more effective than placebo
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068105
06HumanSystematic reviewEfficacy outcome
In adults in randomized trials, tirzepatide 15 mg lowered percent body weight more than placebo (mean difference -12.4%).
In plain wordsIn adults in trials, tirzepatide 15 mg led to a larger percent weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreasePercent weight change versus placebo, 15 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Mean difference in percent weight change
−12.4%
tirzepatide 15 mg vs placebo
Source sentences
Summary
MD in percent change in weight of -8.1% (95% CI -11.0, -5.2; p < 0.001), -11.9% (95% CI -18.1, -5.6; p < 0.001), and -12.4% (95% CI -17.2, -7.5; p < 0.001), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Pooled analysis showed that tirzepatide 5 mg, 10 mg, and 15 mg were more effective than placebo
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068106
07HumanSystematic reviewEfficacy outcome
In adults in randomized trials, tirzepatide reduced BMI.
In plain wordsIn adults in trials, tirzepatide lowered body mass index.
Peptide
Tirzepatide
Outcome
DecreaseBMI
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide also reduced BMI and waist circumference.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068107
08HumanSystematic reviewEfficacy outcome
In adults in randomized trials, tirzepatide reduced waist circumference.
In plain wordsIn adults in trials, tirzepatide reduced waist size.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Tirzepatide also reduced BMI and waist circumference.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068108
09HumanSystematic reviewSafety outcome
In adults in randomized trials, nausea was more common with tirzepatide 15 mg than with placebo (odds ratio 4.2).
In plain wordsIn adults in trials, nausea was more common with tirzepatide 15 mg than with placebo.
Peptide
Tirzepatide
Outcome
IncreaseNausea versus placebo, 15 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mgAs given in this study (human).
Measurements
OR
4.2
nausea, tirzepatide 15 mg vs placebo
Source sentences
Summary
Adverse events were more common with tirzepatide with respect to nausea (OR 4.2; 95% CI 2.4, 7.5; p < 0.001), vomiting (OR 7.0; 95% CI 4.3, 11.4; p < 0.001), and diarrhea (OR 2.8; 95% CI 1.6, 4.9; p < 0.001) (15 mg dose), when compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068109
10HumanSystematic reviewSafety outcome
In adults in randomized trials, vomiting was more common with tirzepatide 15 mg than with placebo (odds ratio 7.0).
In plain wordsIn adults in trials, vomiting was more common with tirzepatide 15 mg than with placebo.
Peptide
Tirzepatide
Outcome
IncreaseVomiting versus placebo, 15 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mgAs given in this study (human).
Measurements
OR
7
vomiting, tirzepatide 15 mg vs placebo
Source sentences
Summary
Adverse events were more common with tirzepatide with respect to nausea (OR 4.2; 95% CI 2.4, 7.5; p < 0.001), vomiting (OR 7.0; 95% CI 4.3, 11.4; p < 0.001), and diarrhea (OR 2.8; 95% CI 1.6, 4.9; p < 0.001) (15 mg dose), when compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068110
11HumanSystematic reviewSafety outcome
In adults in randomized trials, diarrhea was more common with tirzepatide 15 mg than with placebo (odds ratio 2.8).
In plain wordsIn adults in trials, diarrhea was more common with tirzepatide 15 mg than with placebo.
Peptide
Tirzepatide
Outcome
IncreaseDiarrhea versus placebo, 15 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
15 mgAs given in this study (human).
Measurements
OR
2.8
diarrhea, tirzepatide 15 mg vs placebo
Source sentences
Summary
Adverse events were more common with tirzepatide with respect to nausea (OR 4.2; 95% CI 2.4, 7.5; p < 0.001), vomiting (OR 7.0; 95% CI 4.3, 11.4; p < 0.001), and diarrhea (OR 2.8; 95% CI 1.6, 4.9; p < 0.001) (15 mg dose), when compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight.
Summary · context
Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included.
Report a problemFND-3746068111

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.